SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Frequency Therapeutics, Inc. (FREQ) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+367.3%).
- Analyst consensus target $1.40 (+367.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — FREQ
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.44
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-12.48
Book Value / Share$0.00
Revenue / Share$0.68
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$1.40 (+367.3%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-1.68 |
$0.00 |
$-20.24M |
- |
| 2018 |
$-1.59 |
$0.00 |
$-19.17M |
- |
| 2019 |
$-0.52 |
$28.95M |
$-16M |
-55.3% |
| 2020 |
$-0.82 |
$36.98M |
$-26.51M |
-71.7% |
| 2021 |
$-2.47 |
$14.07M |
$-84.69M |
-602% |
| 2022 |
$-2.33 |
$0.00 |
$-81.58M |
- |
| 2024 |
$-9.37 |
$2.27M |
$-83.58M |
-3680.4% |
| 2025 |
$-12.48 |
$6.39M |
$-117.26M |
-1834.5% |
